Patients treated with drug

STO-REC-STAT01M2KJT2 National
10,000

Global · as of 10 Sep 2026

Patients treated with drug stood at 10,000 as of 10 September 2026 (Roche).

Original source
Publisher
Roche
Authority tier
T2 National
Locator
About Enspryng (satralizumab)
Retrieved
15 Sep 2026
Status
Verified

What the source says

Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 10,000 patients.

Verbatim extraction verified: The figure 10,000 is directly attested in the quoted passage (About Enspryng (satralizumab)).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
Roche. (2026). U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-09-10. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA
MLA
Roche. "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments." 2026, https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA.
Chicago
Roche. "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments." 2026. https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA.
BibTeX
@misc{roche2026patientsbjmgda, author = {{Roche}}, title = {U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA}, note = {Original source: https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STAT01M2KJ T2 National

Primary Source

Publisher
Roche · homepage ↗
Authority tier
Tier 2 · National Official
Report
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
Type
Press release
Published
10 September 2026
Locator
About Enspryng (satralizumab)
Retrieved
15 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
15 September 2026
Last revision
15 September 2026
Archival URI
/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA